Six-Month Plans
Mid-term commitments and their break-even.
Mid-term commitments and their break-even.
Across the 20 programmes we price, all-in cost runs from $145 a month at the starter dose, with the cheapest first year at about $1,740 (NexLife, $145 a month at a 2.4 mg maintenance dose). Every figure on this page is on that same all-in basis.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
| Programme | Term | Per month | Twelve months | Saved vs monthly |
|---|---|---|---|---|
| NexLife | 12-month plan | $110 | $1,320 | $420 |
| Yucca Health | 6-month plan | $146 | $1,752 | $0 |
What escalating the dose does to your bill
What the discount costs you
Prepaying lowers the rate and converts a monthly decision into a single non-refundable one. Compounded medication is generally not refundable once it ships, so a term entered during titration puts money at risk against the most likely reason to stop: not tolerating the drug.
The sequencing that protects you is monthly until you have held a maintenance dose for a cycle, prepaid after.
Two questions before committing
Does the discounted rate hold for the whole term or revert at renewal, and what happens if a clinician stops your prescription mid-term. Both answers should be in writing.
What to ask before you enrol
One question does most of the work: what will I pay in total in month six at 2.4 mg, including every fee? A programme that answers in one sentence has flat, all-inclusive pricing. A programme that needs three sentences has a structure worth reading carefully. A programme that cannot answer has told you something.
Then four more: which pharmacy fills the prescription, is the prescriber licensed in my state, does the quoted rate hold at renewal, and what is refundable before shipment.
Where these numbers come from
One dataset, captured 2026-08-05, with a verification status on every record. Prices we read at the provider are tagged as such; figures taken from third-party round-ups are tagged separately and treated as indicative. Where sources disagree we show the conflict rather than choosing. The whole file is downloadable.
Why this distinction changes what you pay
Every structural difference in this market resolves into money at a maintenance dose. Whether a programme charges a membership, whether it reprices with the dose, whether it demands a term, and whether it bundles or splits its charges together account for most of the gap between the cheapest tracked first year at $1,740 and the most expensive.
None of those differences is visible in an advertised headline figure, which is the reason this site exists in the form it does.
How to act on it this week
Price the dose you expect to maintain on rather than the starter dose. Add every recurring fee. Ask whether the quoted rate holds at renewal. Establish who compounds the medicine. And do not enter a prepaid term until you have held a maintenance dose for a cycle.
Those five steps take under an hour and reliably beat any amount of comparison reading, because they surface the information that comparison tables omit.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 20 programmes we price, that runs from $145 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.
4 of those programmes charge a recurring platform fee on top of medication and 19 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
4 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded semaglutide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
How this component moves the total
Across the 20 priced programmes, all-in cost at a maintenance dose spans $145 to $324. Most published comparisons explain that spread as differences in the medicine. It is not: the molecule is identical and frequently comes from the same category of licensed pharmacy.
It is overhead, clinical wrap, pharmacy sourcing and margin — plus the component this page isolates, which is invisible in a single headline figure.
The comparison this makes possible
Once each component is priced separately, two programmes with the same advertised number stop looking equivalent. 4 of 20 charge a mandatory recurring fee; 19 hold one price at every dose. A programme scoring badly on both can advertise the same figure as one scoring well on both.
That is why every table here states all-in cost at a named dose rather than a headline, and why some of our figures are higher than a programme's own homepage.
What to take from this page
One number to carry into any intake conversation: what you will pay in month six at 2.4 mg, including every fee. On the cheapest verified route that is $145. Anything materially below that band, from anyone, deserves the question of which of the four distortions is producing it.
Mid-length terms
Isolating half a year of exposure is the only way two programmes with different structures become comparable. Without it you are ranking marketing decisions rather than costs.
The spread is not marginal. All-in cost at a 2.4 mg maintenance dose runs $145 to $324 across the 20 programmes we price — for the identical molecule, frequently from the same category of licensed pharmacy. Add the brand routes and the same active ingredient spans more than fifteenfold, from a roughly $149 oral option to a list price near $1,349.
The correction worth more than any negotiation: price the dose you expect to hold, add every recurring charge, and compare that figure. On the cheapest verified route it is $145 a month.
What a programme's answer here reveals
A programme that can state this component in one sentence has a simple structure and usually knows it is competitive. One that needs three sentences has a structure worth reading closely — not necessarily a worse deal, but a more conditional one.
One that cannot answer before an intake has made a commercial choice: it wants your contact details and a medical history before you can compare it against anything. That is legal and common, and it is why several programmes on this site carry a page explaining why we publish no figure for them.
Get the answer in writing. Almost every dispute in public complaint records for this category traces back to a number that was never put in an email.
The failure mode this section guards against
Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew.
Each error is small alone and they compound in one direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated. Priced correctly the cheapest verified route sits at $145 a month all-in at a 2.4 mg maintenance dose.
Why we publish the working rather than a verdict
A single recommendation reads better and acts worse, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.
So the tables carry the inputs and every ranking states its sort key. Disagree with our weighting and you can take the file and weight it yourself — which is what publishing it is for.
The number most people get wrong
The month-six figure. Almost everyone budgets from the first month, which on semaglutide describes four weeks at 0.25 mg — roughly 1 mg of active drug against the 9.6 mg a maintenance month delivers.
Ten of your first twelve months are spent at or near maintenance. A ranking sorted on the advertised month is sorting on about eight per cent of your year, and on a dose-scaled programme those are different numbers entirely.
Run the first-year calculator at the dose you expect to hold. It takes under a minute and it reorders the market for most people.
What a year of this actually looks like
Four weeks at 0.25 mg, four at 0.5 mg, four at 1 mg, four at 1.7 mg, then 2.4 mg for the remainder. Sixteen weeks of titration if nothing is repeated, and repeats are common rather than exceptional.
Budget two extra months at a lower tier and treat anything better as upside. Fix a weekly injection day, record dose and date, and diary the renewal date if an introductory rate applies — the reversion is where most complaints in this category begin.
Putting six-month plans in proportion
It is one input into a decision with three parts: what you pay at the dose you hold, who makes what you inject, and what happens if you stop. Weighting one to the exclusion of the others is how people end up on a cheap programme they abandon in month nine.
The frame: 20 programmes publish a capturable price, spanning $145 to $324 a month all-in at a 2.4 mg maintenance dose. 4 charge a mandatory recurring fee. 6 name the dispensing pharmacy before purchase.
What good looks like
A figure at a named dose, the pharmacy named, cancellation terms published before payment, and a plain statement that a compounded preparation is not FDA-approved. Four things, all cheap to publish, and a minority does all four.
The cheapest verified route sits at $145 a month, which establishes that disclosure and low price are not in tension.
What to ask before you pay
Five questions, all answerable in a short email, all before a medical history changes hands: the total at a maintenance dose including every fee; which pharmacy fills it; whether the prescriber is licensed in your state; the notice period to cancel and what is refundable; and which form of the active ingredient the pharmacy compounds from.
None requires clinical training to evaluate. The speed and specificity of the reply tells you how the operation is run, and it arrives before your money does.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.